Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Phase 2CompletedNCT00189722

Astellas Pharma Inc160 enrolled

Overview

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

160

Conditions

Asthma, Bronchial Bronchial Asthma

Interventions

TacrolimusDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of asthma * Patients treated with inhaled corticosteroid and long acting beta 2 agonist * FEV1(forced expiratory volume in 1 second)\>50% to 80% Exclusion Criteria: * Respiratory infection within 2weeks * Asthma exacerbation within 6 weeks

Locations (28)

Unnamed facility

Brno, Czechia

Unnamed facility

Krhanice, Czechia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.